JP2023528421A - キナーゼ阻害剤 - Google Patents

キナーゼ阻害剤 Download PDF

Info

Publication number
JP2023528421A
JP2023528421A JP2022574229A JP2022574229A JP2023528421A JP 2023528421 A JP2023528421 A JP 2023528421A JP 2022574229 A JP2022574229 A JP 2022574229A JP 2022574229 A JP2022574229 A JP 2022574229A JP 2023528421 A JP2023528421 A JP 2023528421A
Authority
JP
Japan
Prior art keywords
formula
compound
pharmaceutically acceptable
acceptable salt
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022574229A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528421A5 (https=
JPWO2021247748A5 (https=
Inventor
アラン コバーン、クレイグ
ヴィジェイ クマール、ダンジェ
ジョン ブザード、ダニエル
アローラ、ニディ
Original Assignee
ジービー００５， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジービー００５， インコーポレイテッド filed Critical ジービー００５， インコーポレイテッド
Publication of JP2023528421A publication Critical patent/JP2023528421A/ja
Publication of JP2023528421A5 publication Critical patent/JP2023528421A5/ja
Publication of JPWO2021247748A5 publication Critical patent/JPWO2021247748A5/ja
Priority to JP2025207773A priority Critical patent/JP2026048716A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022574229A 2020-06-02 2021-06-02 キナーゼ阻害剤 Pending JP2023528421A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025207773A JP2026048716A (ja) 2020-06-02 2025-11-28 キナーゼ阻害剤

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063033729P 2020-06-02 2020-06-02
US202063033728P 2020-06-02 2020-06-02
US202063033724P 2020-06-02 2020-06-02
US63/033,724 2020-06-02
US63/033,728 2020-06-02
US63/033,729 2020-06-02
US202163136593P 2021-01-12 2021-01-12
US202163136587P 2021-01-12 2021-01-12
US202163136577P 2021-01-12 2021-01-12
US63/136,577 2021-01-12
US63/136,587 2021-01-12
US63/136,593 2021-01-12
PCT/US2021/035509 WO2021247748A1 (en) 2020-06-02 2021-06-02 Kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025207773A Division JP2026048716A (ja) 2020-06-02 2025-11-28 キナーゼ阻害剤

Publications (3)

Publication Number Publication Date
JP2023528421A true JP2023528421A (ja) 2023-07-04
JP2023528421A5 JP2023528421A5 (https=) 2024-06-10
JPWO2021247748A5 JPWO2021247748A5 (https=) 2024-06-10

Family

ID=76601840

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022574229A Pending JP2023528421A (ja) 2020-06-02 2021-06-02 キナーゼ阻害剤
JP2025207773A Pending JP2026048716A (ja) 2020-06-02 2025-11-28 キナーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025207773A Pending JP2026048716A (ja) 2020-06-02 2025-11-28 キナーゼ阻害剤

Country Status (7)

Country Link
US (1) US12448363B2 (https=)
EP (1) EP4157446A1 (https=)
JP (2) JP2023528421A (https=)
CN (1) CN115867346B (https=)
AU (1) AU2021283916A1 (https=)
CA (1) CA3179637A1 (https=)
WO (1) WO2021247748A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021398051A1 (en) 2020-12-10 2023-07-27 Principia Biopharma Inc. Crystal form of tolebrutinib, preparation method therefor and use thereof
CN117915960A (zh) * 2021-08-30 2024-04-19 百时美施贵宝公司 可用于布鲁顿酪氨酸激酶的pet成像的化合物
WO2023227080A1 (zh) * 2022-05-25 2023-11-30 百极弘烨(南通)医药科技有限公司 一种protac化合物、含其的药物组合物及其制备方法和应用
JP2025521510A (ja) * 2022-06-22 2025-07-10 プリンシピア バイオファーマ インコーポレイテッド 改変されたｂｔｋ阻害剤の作製方法
CN116284025B (zh) * 2023-02-20 2025-07-04 国科大杭州高等研究院 一种具有抗癌作用的螺杂环类化合物、药物组合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523911A (ja) * 2013-06-26 2016-08-12 アッヴィ・インコーポレイテッド Ｂｔｋ阻害薬としての一級カルボキサミド類
JP2017531679A (ja) * 2014-10-24 2017-10-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ キナーゼ阻害剤として有用なインドールカルボキシアミド

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3209651T1 (sl) * 2014-10-24 2019-12-31 Bristol-Myers Squibb Company Derivati karbazola

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523911A (ja) * 2013-06-26 2016-08-12 アッヴィ・インコーポレイテッド Ｂｔｋ阻害薬としての一級カルボキサミド類
JP2017531679A (ja) * 2014-10-24 2017-10-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ キナーゼ阻害剤として有用なインドールカルボキシアミド

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCOTT H. WATTERSON ET AL.: ""Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, no. 7, JPN6025006165, 20 March 2019 (2019-03-20), pages 3228 - 3250, ISSN: 0005651407 *
野崎 正勝 他, 創薬化学, vol. 第1版, JPN7023001664, 1995, JP, pages 98 - 99, ISSN: 0005651408 *

Also Published As

Publication number Publication date
EP4157446A1 (en) 2023-04-05
CN115867346B (zh) 2025-03-14
WO2021247748A1 (en) 2021-12-09
CA3179637A1 (en) 2021-12-09
US20230219923A1 (en) 2023-07-13
AU2021283916A1 (en) 2023-01-05
CN115867346A (zh) 2023-03-28
JP2026048716A (ja) 2026-03-17
US12448363B2 (en) 2025-10-21

Similar Documents

Publication Publication Date Title
KR102317480B1 (ko) Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
TWI850648B (zh) 作為jak1抑制劑之哌啶-4-基三亞甲亞胺衍生物
DK3126330T3 (en) BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
TWI789381B (zh) 雜環化合物
JP6802263B2 (ja) Ｔｙｋ２阻害剤およびその使用
WO2023061294A1 (zh) 含氮杂环类衍生物调节剂、其制备方法及应用
JP2023528421A (ja) キナーゼ阻害剤
TW202200543A (zh) Mdm2降解劑及其用途
JP2026503019A (ja) Ｖａｖ１の標的化分解
US20240246977A1 (en) Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and method of use
JP2026508745A (ja) アミド又はウレア系化合物
TW202508568A (zh) Ｉｒａｋ４蛋白水解靶向嵌合體
TW202122382A (zh) 乙內醯脲衍生物
CN108721298A (zh) 作为布鲁顿酪氨酸激酶抑制剂的嘧啶并杂环化合物及其应用
TW202334151A (zh) Tyk2降解劑及其用途
JP2026059800A (ja) Ｉｒａｋデグレーダー及びその使用
JP2023521172A (ja) キナーゼ阻害剤
TW202517653A (zh) 治療自體免疫疾病之大環
AU2022209175A1 (en) Indole derivatives as kinase inhibitors
WO2023230609A1 (en) Heterocyclic pad4 inhibitors
TW202417434A (zh) 用於治療之parp14之靶向蛋白質降解
KR20190007391A (ko) 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
HK1234395B (zh) 双环稠合的杂芳基或芳基化合物以及它们作为irak4拟制剂的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250708

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250729